459 692

Cited 4 times in

Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial

DC Field Value Language
dc.contributor.author권유진-
dc.contributor.author남정모-
dc.contributor.author이지원-
dc.contributor.author이향규-
dc.contributor.author이혜선-
dc.contributor.author장혁재-
dc.date.accessioned2021-04-29T17:09:43Z-
dc.date.available2021-04-29T17:09:43Z-
dc.date.issued2021-03-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182211-
dc.description.abstractBackground: In clinical practice, concomitant treatment of orlistat with phentermine is commonly used off-label. However, clinical trials have not been performed to evaluate whether their combination improves metabolic parameters and cardiovascular risk factors other than weight loss. Therefore, we aimed to compare the efficacy of concomitant administration of orlistat and phentermine versus phentermine alone on the endothelial cell function in overweight and obese adults with back pain. Methods: We conducted a 12-week, double-blinded, placebo-controlled clinical trial involving 114 patients with a body mass index of ≥30 (obese) or ≥27 (overweight) with weight-related comorbidities. We randomly assigned patients in a 1:1 ratio to receive orlistat (120mg) three times daily and phentermine (37.5mg) once daily, or a placebo three times daily and phentermine (37.5mg) once daily. Primary endpoint was changes in endothelium-dependent vasodilatation measured using ultrasound assessment of flow-mediated dilatation (FMD). Differences within groups after intervention were compared using the paired t-test or Wilcoxon signed-rank test. Differences in changes between the groups were calculated using an analysis of covariance after adjusting for each baseline value. Results: Mean weight loss during the 12-week study period was 6.1kg in the orlistat/phentermine group and in the placebo/phentermine group. Adjusted mean changes in total and non-high-density lipoprotein cholesterol were significantly greater in the orlistat/phentermine group than in the placebo/phentermine group. Adjusted mean changes in endothelium-dependent FMD were significantly greater in the orlistat/phentermine group than in the placebo/phentermine group (4.97±0.98% vs 2.05±0.99%, respectively; p=0.038). Changes in endothelium-independent nitroglycerin-mediated dilatation were not significantly different between the groups. Conclusion: Orlistat/phentermine significantly improved the vascular endothelial cell function compared with phentermine alone. Orlistat might have beneficial effects on the decrease of the risk of cardiovascular disease, especially in overweight and obese patients with comorbidities.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherDove Medical Press-
dc.relation.isPartOfDIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEffects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Family Medicine (가정의학교실)-
dc.contributor.googleauthorYu-Jin Kwon-
dc.contributor.googleauthorHyangkyu Lee-
dc.contributor.googleauthorChung Mo Nam-
dc.contributor.googleauthorHyuk-Jae Chang-
dc.contributor.googleauthorYoung-Ran Yoon-
dc.contributor.googleauthorHye Sun Lee-
dc.contributor.googleauthorJi-Won Lee-
dc.identifier.doi10.2147/DMSO.S300342-
dc.contributor.localIdA04882-
dc.contributor.localIdA01264-
dc.contributor.localIdA03203-
dc.contributor.localIdA03282-
dc.contributor.localIdA03312-
dc.contributor.localIdA03490-
dc.relation.journalcodeJ03921-
dc.identifier.eissn1178-7007-
dc.identifier.pmid33688228-
dc.subject.keywordendothelial cell function-
dc.subject.keywordobesity-
dc.subject.keywordorlistat-
dc.subject.keywordphentermine-
dc.contributor.alternativeNameKwon, Yu-Jin-
dc.contributor.affiliatedAuthor권유진-
dc.contributor.affiliatedAuthor남정모-
dc.contributor.affiliatedAuthor이지원-
dc.contributor.affiliatedAuthor이향규-
dc.contributor.affiliatedAuthor이혜선-
dc.contributor.affiliatedAuthor장혁재-
dc.citation.volume14-
dc.citation.startPage941-
dc.citation.endPage950-
dc.identifier.bibliographicCitationDIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, Vol.14 : 941-950, 2021-03-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Family Medicine (가정의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
3. College of Nursing (간호대학) > Dept. of Nursing (간호학과) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.